Vanda Pharmaceuticals (VNDA) Cash Flow Statement

Click line-items for a historical chart and %

Cash flows from operating activities
Net income (loss)	-17.41M
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization
Employee and non-employee stock-based compensation	6.44M
Loss on disposal of assets
Amortization of premiums and discounts on marketable securities	76K
Amortization of intangible asset	8.83M
Deferred tax benefit
Changes in assets and liabilities:
Accounts receivable	52K
Inventory	63K
Prepaid expenses, deposits and other current assets	-5.4M
Accounts payable
Accrued liabilities
Accrued income taxes
Other liabilities
Deferred revenue
Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment	-710K
Proceeds from sale of property and equipment
Purchases of marketable securities	-130.86M
Maturities of marketable securities
Change in restricted cash
Net cash provided by (used in) investing activities
Cash flows from financing activities
Excess tax benefits from stock-based compensation
Proceeds from exercise of stock options
Net cash provided by financing activities
Net change in cash and cash equivalents	-18.08M
Cash and cash equivalents
Beginning of period	50.84M
End of period	32.77M

Entities mentioned with VNDA